Activated phosphoinositide 3-kinase delta syndrome: Pathogenesis, clinical manifestations, and treatment

Abstract

Activated phosphoinositide 3-kinase delta syndrome (APDS) is an autosomal dominant inborn errors of immunity resulting from gain of function mutations in the PIK3CD gene or loss of function mutations in the PIK3R1 gene. These mutations lead to hyperactivation of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathways, causing complex deficiencies in cellular and humoral immunity. APDS patients exhibit diverse clinical manifestations including recurrent respiratory infections, nonneoplastic lymphoproliferation, an increasing risk of malignancy, and autoimmune diseases. Neurodevelopmental abnormalities, short stature, failure to thrive, and psychological disorders are also observed. Management strategies for APDS involve antibiotic prophylaxis and immunoglobulin replacement therapy, immunosuppressive therapies, and hematopoietic stem cell transplantation for severe cases. Targeted therapies, such as the mTOR inhibitor sirolimus and the elective Phosphoinositide 3-kinase delta inhibitor leniolisib, have emerged as promising options, demonstrating both safety and effectiveness. Continuous monitoring and further research are essential to optimize treatment strategies and understand the long-term implications of these interventions. This review aims to summarize the pathogenesis, clinical manifestations, and treatment of APDS.

Keywords

activated phosphoinositide 3-kinase delta syndrome / hematopoietic stem cell transplantation / inborn errors of immunity / targeted therapy

References

[1] BousfihaA, Moundir A, TangyeSG, et al. The 2022 update of IUIS phenotypical classification for human inborn errors of immunity. J Clin Immunol. 2022;42(7):1508-1520.

[2] AnguloI, VadasO, GarçonF, et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science. 2013;342(6160):866-871.

[3] DeauMC, Heurtier L, FrangeP, et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J Clin Invest. 2014;124(9):3923-3928.

[4] LucasCL, Chandra A, NejentsevS, CondliffeAM, Okkenhaug K. PI3Kδ and primary immunodeficiencies. Nat Rev Immunol. 2016;16(11):702-714.

[5] KoyasuS. The role of PI3K in immune cells. Nat Immunol. 2003;4(4):313-319.

[6] CoulterTI, Chandra A, BaconCM, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597-606.e4.

[7] WangW-J, MinQ, LaiN-N, et al. Cellular mechanisms underlying B cell abnormalities in patients with gain-of-function mutations in the PIK3CD gene. Front Immunol. 2022;13:890073.

[8] PoggiL, Chentout L, LizotS, et al. Rescuing the cytolytic function of APDS1 patient T cells via TALEN-mediated PIK3CD gene correction. Mol Ther Methods Clin Dev. 2023;31:101133.

[9] VanselowS, Hanitsch L, HauckF, et al. Future directions in the diagnosis and treatment of APDS and IEI: a survey of German IEI centers. Front Immunol. 2023;14:1279652.

[10] CrankMC, Grossman JK, MoirS, et al. Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility. J Clin Immunol. 2014;34(3):272-276.

[11] JiaY-J, YangQ-Y, WangY-P, et al. Hyperactive PI3Kδ predisposes naive T cells to activation via aerobic glycolysis programs. Cell Mol Immunol. 2021;18(7):1783-1797.

[12] BierRG, PayneK, et al. Activating mutations in PIK3CD disrupt the differentiation and function of human and murine CD4⁺ T cells. J Allergy Clin Immunol. 2019;144(1):236-253.

[13] CondliffeAM, Chandra A. Respiratory manifestations of the activated phosphoinositide 3-kinase delta syndrome. Front Immunol. 2018;9:338.

[14] JameeM, MoniriS, Zaki-DizajiM, et al. Clinical, immunological, and genetic features in patients with activated PI3Kδ syndrome (APDS):a systematic review. Clin Rev Allergy Immunol. 2020;59(3):323-333.

[15] GathmannB, Mahlaoui N, GérardL, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014;134(1):116-126.

[16] RamirezL, TamayoW, AleH. APDS2 and SHORT syndrome in a teenager with PIK3R1 pathogenic variant. J Clin Immunol. 2020;40(7):1020-1025.

[17] CarpierJM, LucasCL. Epstein-Barr virus susceptibility in activated PI3Kδ syndrome (APDS) immunodeficiency. Front Immunol. 2018;8:2005.

[18] OlbrichP, LorenzM, Cura DaballP, et al. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature. Pediatr Allergy Immunol. 2016;27(6):640-644.

[19] EwertowskaM, Grześk E, UrbańczykA, et al. Activated phosphoinositide 3-kinase delta syndrome 1 and 2 (APDS 1 and APDS 2):similarities and differences based on clinical presentation in two boys. Allergy Asthma Clin Immunol. 2020;16:22.

[20] SinghA, JoshiV, JindalAK, Mathew B, RawatA. An updated review on activated PI₃ kinase delta syndrome (APDS). Genes Dis. 2019;7(1):67-74.

[21] PhamMN, Cunningham-Rundles C. Evaluation of lymphoproliferative disease and increased risk of lymphoma in activated phosphoinositide 3 kinase delta syndrome: a case report with discussion. Front Pediatr. 2018;6:402.

[22] SuarezF, Lortholary O, HermineO, LecuitM. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107(8):3034-3044.

[23] StarkAK, Sriskantharajah S, HesselEM, OkkenhaugK. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;23:82-91.

[24] PreiteS, Cannons JL, RadtkeAJ, et al. Hyperactivated PI3Kδ promotes self and commensal reactivity at the expense of optimal humoral immunity. Nat Immunol. 2018;19(9):986-1000.

[25] ChakravortyS, AfzaliB, KazemianM. EBV-associated diseases: current therapeutics and emerging technologies. Front Immunol. 2022;13:1059133.

[26] ElkaimE, NevenB, BruneauJ, et al. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: a cohort study. J Allergy Clin Immunol. 2016;138(1):210-218.e9.

[27] BloomfieldM, Klocperk A, ZachovaR, MilotaT, Kanderova V, SedivaA. Natural course of activated phosphoinositide 3-kinase delta syndrome in childhood and adolescence. Front Pediatr. 2021;9:697706.

[28] Moreno-CoronaN, Chentout L, PoggiL, et al. Two monogenetic disorders, activated PI₃-Kinase-δ syndrome 2 and Smith-magenis syndrome, in one patient: case report and a literature review of neurodevelopmental impact in primary immunodeficiencies associated with disturbed PI3K signaling. Front Pediatr. 2021;9:688022.

[29] MichalovichD, Nejentsev S. Activated PI₃ kinase delta syndrome: from genetics to therapy. Front Immunol. 2018;9:369.

[30] OhJ, Garabedian E, FuleihanR, Cunningham-RundlesC. Clinical manifestations and outcomes of activated phosphoinositide 3-kinase δ syndrome from the USIDNET cohort. J Allergy Clin Immunol Pract. 2021;9(11):4095-4102.

[31] MaccariME, Abolhassani H, AghamohammadiA, et al. Disease evolution and response to rapamycin in activated phosphoinositide 3-kinase δ syndrome: the European society for immunodeficiencies-activated phosphoinositide 3-kinase δ syndrome registry. Front Immunol. 2018;9:543.

[32] EdgarJDM, Richter AG, HuissoonAP, et al. Prescribing immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and republic of Ireland. J Clin Immunol. 2018;38(2):204-213.

[33] BergerM, JollesS, OrangeJS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol. 2013;33(5):984-990.

[34] ElgizouliM, LoweDM, SpeckmannC, et al. Activating PI3Kδ mutations in a cohort of 669 patients with primary immunodeficiency. Clin Exp Immunol. 2016;183(2):221-229.

[35] NotarangeloLD. Hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: who, when, and how? J Allergy Clin Immunol. 2019;143(1):91-93.

[36] NademiZ, Slatter MA, DvorakCC, et al. Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome. J Allergy Clin Immunol. 2017;139(3):1046-1049.

[37] OkanoT, ImaiK, TsujitaY, et al. Hematopoietic stem cell transplantation for progressive combined immunodeficiency and lymphoproliferation in patients with activated phosphatidylinositol-3-OH kinase δ syndrome type 1. J Allergy Clin Immunol. 2019;143(1):266-275.

[38] QiuL-Y, WangY-P, TangW-J, et al. Activated phosphoinositide 3-kinase δ syndrome: a large pediatric cohort from a single center in China. J Clin Immunol. 2022;42(4):837-850.

[39] DimitrovaD, NademiZ, MaccariME, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2022;149(1):410-421.e7.

[40] AlbertMH, Slatter MA, GenneryAR, et al. Hematopoietic stem cell transplantation for wiskott-aldrich syndrome: an EBMT inborn ErrorsWorking party analysis. Blood. 2022;139(13):2066-2079.

[41] QuintiI, Soresina A, SpadaroG, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27(3):308-316.

[42] HartmanHN, Niemela J, HintermeyerMK, et al. Gain of function mutations of PIK3CD as a cause of primary sclerosing cholangitis. J Clin Immunol. 2015;35(1):11-14.

[43] RaeW, Ramakrishnan KA, GaoY-F, et al. Precision treatment with sirolimus in a case of activated phosphoinositide 3-kinase δ syndrome. Clin Immunol. 2016;171:38-40.

[44] Guerau-de-ArellanoM, Piedra-Quintero ZL, TsichlisPN. AKT isoforms in the immune system. Front Immunol. 2022;13:990874.

[45] WangX, DingJ, MengL-H. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies. Acta Pharmacol Sin. 2015;36(10):1170-1176.

[46] FagoneE, Fruciano M, GiliE, SambataroG, Vancheri C. Developing PI3K inhibitors for respiratory diseases. Curr Top Microbiol Immunol. 2022;436:437-466.

[47] RaoVK, Webster S, ŠediváA, et al. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome. Blood. 2023;141(9):971-983.

[48] RaoVK, KulmE, ŠediváA, et al. Interim analysis: open-label extension study of leniolisib for patients with APDS. J Allergy Clin Immunol. 2024;153(1):265-274.e9.

[49] StarkAK, Chandra A, ChakrabortyK, et al. PI3Kδ hyper-activation promotes development of B cells that exacerbate Streptococcus pneumoniae infection in an antibody-independent manner. Nat Commun. 2018;9(1):3174.

[50] BeggM, AmourA, JarvisE, et al. An open label trial of nemiralisib, an inhaled PI₃ kinase delta inhibitor for the treatment of Activated PI₃ kinase Delta Syndrome. Pulm Pharmacol Ther. 2023;79:102201.

RIGHTS & PERMISSIONS

2024 The Author(s). Pediatric Discovery published by John Wiley & Sons Australia, Ltd on behalf of Children’s Hospital of Chongqing Medical University.